Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitor angioedema onset is delayed
Safety · ACEARB-SAFE-04 · v2
This claim says that ACE-inhibitor angioedema usually shows up only after months or years on the drug. The large patient studies in this corpus point the other way: the reaction is most common right after starting treatment, with the risk highest in the first week [1], the first 30 days [2][5], and within the first 90 days for most people [15][4]. A randomized trial saw the rate highest soon after starting and then falling [3]. Delayed reactions after years are real, shown by individual case reports [20][17], and a low background risk does continue year after year [11], but that is the exception rather than the rule. Because the claim's key word is 'typically', and the typical pattern in this corpus is early onset, the panel found the claim contradicted.
Across the largest datasets, onset clusters early: [1] found angioedema during the first week at one case per 3000 patients per week, with the incidence 14-fold lower thereafter; [2] reported a relative risk of 4.6 in the first 30 days versus more than one year of use; [5] found incidence greatest in the first 30 days; and [15] found 55% of cases occurred within 90 days of first use. The only randomized trial [3] found incidence higher after initiation (3.6 per 1000 per month) declining to 0.4 per 1000 per month, concluding it is most likely early but may occur at any time. [4] reported durations from 1 day to 5 years but 21 of 32 within 2 months. Delayed onset is documented as a minority pattern: [11] found a persistent, relatively constant annual risk of 0.10% to 0.12% after the first year, and late cases appear at 5 years [20] and about 6 weeks [22]. The contested point: The evidence divides on whether delayed onset is common or merely possible: [17] states 30% of patients take the drug for years before angioedema develops, and [11] documents a persistent multi-year risk, yet neither establishes that the majority of cases arise after months to years. The split is between genuine late-onset occurrence and what is typical.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim's operative word is 'typically' (majority). Every large dataset [1][2][3][4][5][11][15] places the peak and the majority of events in the first week to first 90 days; none reports a median onset in months to years.
Late-onset case reports [17][20][22] prove delayed onset is possible but cannot speak to what is typical; using them to support the claim is base-rate neglect — [17] itself puts the delayed group at only 30%.
Where it remains uncertain. Late onset is real and can occur at any time [20][11][17], but the corpus does not show it as the typical pattern.
Aleatory
Onset timing is inherently variable; [3] concludes it may occur at any time and [20] documents onset after 5 years, so individual timing is not deterministic.
Epistemic
[5] followed initiators for a maximum of 1 year, so events beyond that window are unobservable in that cohort and the long tail is undercounted.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Early peak with a persistent but lower later risk — delayed onset occurs but is not the majority.
“We identified a 0.07% incidence of ACEI angioedema within 1 month of prescription and a 0.23% incidence during the first year. Incidence of angioedema was relatively constant annually over the subsequent 4 years (0.10% to 0.12%).”
Panel auditInternal validity: high · scope of inference: Outpatients at one US academic centre prescribed ACEIs, 2000-2008.Key limitations: EHR-coded reaction definition · no statistical test on timing · single centre
Documents that delayed onset after years can occur (single case).
“developed ACE inhibitor-induced angioedema after 5 years of daily ramipril administration”
Panel auditInternal validity: low · scope of inference: One 89-year-old woman who developed angioedema after 5 years of ramipril.Key limitations: n=1 · typicality not inferable from a case
Largest early dataset shows onset concentrated in week 1, directly against delayed-onset claim.
“angioedema in association with the angiotensin converting-enzyme inhibitor enalapril maleate occurred during the first week of therapy at the rate of one case per 3000 patients per week. Thereafter, the incidence was 14-fold lower, without evidence of a temporal trend in incidence beyond the first week of therapy.”
Panel auditInternal validity: medium · scope of inference: Enalapril-treated patients across controlled and marketed experience, 1980s.Key limitations: descriptive pooling · no CI or p for timing · single-drug (enalapril)
Enalapril is listed as a home medication but the duration of use before symptom onset is not given, so onset timing cannot be read.
Panel auditInternal validity: low · scope of inference: One enalapril-treated patient with isolated supraglottic angioedema.Key limitations: n=1 · treatment duration before onset not stated
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus robustly shows most ACEi-induced angioedema arises early, refuting the claim that it typically develops only after months to years.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No reported median time-to-onset. The verdict on 'typically' rests on where events concentrate, but no included study states a median onset, so the central tendency is inferred rather than measured. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort with complete long-term follow-up reporting the distribution and median of time-from-initiation to onset.
Open question: What is the median time from ACE-inhibitor initiation to angioedema onset in a cohort with long, complete follow-up? Why it is still open: No corpus study reports a median onset; timing is given only as early-window incidence rates and relative risks [1][2][3][5][15].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19